Disseminated on behalf of Helus Pharma Inc., may include paid advertisements. Investment Considerations HLP003 is in Phase 3 development with FDA Breakthrough Therapy Designation for adjunctive treatment of major depressive disorder. Twelve-month data following two 16 mg doses demonstrated sustained improvements in depression symptoms, including 100% responder and 71% remission rates in the analyzed cohort. … Continue reading “Helus Pharma Inc. (NASDAQ: HELP) (NEO: HELP)”
| Symbol | Release | Time |
|---|---|---|
| {{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |